Lupin Limited – Investor Presentation Summary

Key Operational Highlights

  • Net Sales reached ₹82,172 crore in Q1 FY27, representing 33.3% YoY growth
  • India business grew approximately 14% YoY with highest quarterly sales in last six quarters
  • Diagnostics platform served around 7+ lakh patients during the quarter
  • Onboarded approximately 10,000 cardiac patients through digital offerings during the quarter
  • 22,400+ patients covered under "Lives Program" with community health screenings

Key drivers of operational performance: New product launches, geographic expansion including first entry into China market, digital healthcare initiatives, and diagnostics platform expansion.

Segment-wise Performance

  • United States sales (includes IP income): Specific figures not disclosed but mentioned sustained growth
  • India Formulations: ~14% YoY growth, aiming to outperform Indian Pharmaceutical Market (IPM) by 1.2-1.3x
  • Other Developed Markets (Canada, Australia, Europe & Others): Operating leverage across platforms
  • Emerging Markets (LATAM, South Africa, Philippines & RoW): Global reach as partner of choice
  • API Business: Substantial scale achieving reliability of supply and cost position

Explanation of significant changes in segment performance: Growth driven by portfolio execution in US, market outperformance in India, and strategic partnerships in international markets.

Financial Highlights

Revenue: ₹82,172 crore (Net Sales)

EBITDA: ₹24,635 crore (30.0% margin)

PAT: Net Income of ₹14,150 crore (17.2% margin)

YoY/QoQ comparison:

  • Net Sales: +33.3% YoY, +11.2% QoQ
  • EBITDA: +50.1% YoY, +13.5% QoQ
  • Net Income: +16.1% YoY, -3.1% QoQ (Q4FY26 included net one-time exceptional expense of ₹1,313 crore)

Drivers of financial performance: Higher revenue growth, improved operational efficiencies, and market expansion.

Key Risks: Raw material availability, regulatory compliance challenges, technological advances by competitors, and healthcare reforms mentioned in forward-looking statements.

Geographical Revenue Split

Domestic vs Export/Regional Revenue:

  • Domestic (India): Specific values not disclosed but ~14% YoY growth
  • Export/International: United States, Other Developed Markets, and Emerging Markets

Regional Breakdown: United States, Canada, Australia, Europe, LATAM, South Africa, Philippines, and Rest of World.

Balance Sheet Snapshot

Specific balance sheet metrics not provided in the presentation.

Capex & Cash Flow Health

  • R&D as % of Sales: Calculated basis Net Sales excluding Other Operating Income (specific percentage not disclosed)
  • Capex as % of Sales: Calculated basis Net Sales excluding Other Operating Income (specific percentage not disclosed)

Investment Rationale: Focus on complex generics, biosimilars, capacity expansion, and technology upgrades.

Strategic & R&D Initiatives

Investments in Innovation:

  • 20 complex product launches in inhalation, injectables, ophthalmics by 2028
  • 5 biosimilar filings in regulated markets by 2028
  • 10 novel complex pipeline products in India by 2028
  • LNP8701 (novel SOS1 inhibitor) Phase 1a data accepted for publication at ASCO 2026

Expected impact on growth: Building emerging therapies including dedicated division for Semaglutide across Diabetology/Endocrinology & Gastroenterology/Gynecology.

Strategic Rationale: Expanding into high-growth markets, reducing operational costs through operating leverage, and becoming CGx powerhouse.

Industry Trends & Business Environment

Macro/Industry Trends: Domestic and international healthcare reforms, trends toward managed care and healthcare cost containment, regulatory environment changes.

Impact on Company: Affecting manufacturing and marketing risks, regulatory approval processes, and product development timelines.

Management Commentary & Growth Outlook

Strategic Outlook: "Paving a sustainable future for Planet, People and Patients" with focus on ESG leadership

FY Guidance: Plan to launch 20+ products in FY27 in India; Target 70% chronic share by FY31; IRF poised to outperform IPM by 1.2-1.3x

Market Share Targets: Global No 1 in ESG rating in pharma sector; No 1 in India across all sectors in S&P Global ESG Ratings

Risks and Opportunities: General industry and market conditions, geopolitical risks, currency exchange fluctuations, product development challenges, and manufacturing/marketing uncertainties.

ESG Updates

  • Global #1 in Pharma Sector ESG rating (91/100 S&P Global ESG Rating)
  • 48% share of renewable energy
  • 5 years of water positivity in a row
  • Featured in TIME World's Most Sustainable Companies 2026 List
  • Listed in Dow Jones Best-in-Class World Index and Emerging Markets Index
  • 'A' leadership rating in Climate & Water in 2025 (up from F in 2021)
  • 'BBB' ESG rating in 2025 (up from BB in 2024)
  • 71/100 ESG rating score for FY2025
  • 35,400+ employee volunteering hours (target 50,000 by 2030)
  • 17% supplier sustainability assessment ongoing engagement
  • 980,000 patients educated (target 3 million by 2030)
  • 73,500 doctors engaged (target 50,000 by 2030)
  • 510,000+ beneficiaries impacted under Lives & Livelihood program